RMIT University
Browse

Lamellar crystalline self-assembly behaviour and solid lipid nanoparticles of a palmityl prodrug analogue of Capecitabine-A chemotherapy agent

journal contribution
posted on 2024-11-01, 10:04 authored by X Gong, M.J. Moghaddam, S Sagnella, Charlotte ConnCharlotte Conn, S Danon, Lynne Waddington, Calum DrummondCalum Drummond
An amphiphile prodrug, 5'-deoxy-5-fluoro-N(4)- (palmityloxycarbonyl) cytidine or 5'-deoxy-5-fluoro-N(4)-(hexadecanaloxycarbonyl) cytidine (5-FCPal), consisting of the same head group as the commercially available chemotherapeutic agent Capecitabine, linked to a palmityl hydrocarbon chain via a carbamate bond is reported. Thermal analysis of this prodrug indicates that it melts at similar to 115 degrees C followed quickly by degradation beginning at similar to 120 degrees C. The neat solid 5-FCPal amphiphile acquires a lamellar crystalline arrangement with a d-spacing of 28.6 +/- 0.3 angstrom, indicating interdigitation of the hydrocarbon chains. Under aqueous conditions, solid 5-FCPal is non-swelling and no lyotropic liquid crystalline phase formation is observed. In order to assess the in vitro toxicity and in vivo efficacy in colloidal form, solid lipid nanopartides (SLNs) with an average size of similar to 700 nm were produced via high pressure homogenization. The in vitro toxicity of the 5-FCPal SLNs against several different cancer and normal cell types was assessed over a 48 h period, and IC(50) values were comparable to those observed for Capecitabine. The in vivo efficacy of the 5-FCPal SLNs was then assessed against the highly aggressive mouse 4T1 breast cancer model. To do so, the prodrug SLNs were administered orally at 3 different dosages (0.1, 0.25, 0.5 mmol/mouse/day) and compared to Capecitabine delivered at the same dosages. After 21 days of receiving the treatments, the 0.5 mmol dose of 5-FCPal exhibited the smallest average tumour volume. Since 5-FCPal is activated in a similar manner to Capecitabine via a 3 step enzymatic pathway with the final step occurring preferentially at the tumour site, formulation of the prodrug into SLNs combines the advantage of selective, localized activation with the sustained release properties of nanostructured amphiphile self-assembly and multiple payload materials thereby potentially creating a more effective antic

History

Related Materials

  1. 1.
    DOI - Is published in 10.1016/j.colsurfb.2011.03.007
  2. 2.
    ISSN - Is published in 09277765

Journal

Colloids and Surfaces B: Biointerfaces

Volume

85

Issue

2

Start page

349

End page

359

Total pages

11

Publisher

Elsevier BV

Place published

Netherlands

Language

English

Copyright

© 2011 Published by Elsevier

Former Identifier

2006044220

Esploro creation date

2020-06-22

Fedora creation date

2014-11-05

Usage metrics

    Scholarly Works

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC